Skip to main content

Table 2 Study population characteristics

From: Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis

First author (Ref. No.) Population BL RAAS blockade Tx age Ct age Tx gender (F:M or % male) Ct gender (F:M or % male) Tx SUA baseline (mg/dL) Ct SUA baseline (mg/dL)
Katholi [51] sCr 1.4-2.0 mg/dl and rec contrast Excluded 60 ± 4 (NMg), 61 ± 3 (LoMg) 59 ± 5 (NMg), 63 ± 4 (LoMg) Not reported Not reported Not reported Not reported
Perez-Ruiz [56] Chronic Gout with CrCl 20-80 Not reported 60.9 ± 12.8 67.3 ± 9.59 Not reported Not reported 9.35 ± 1.96 8.96 ± 1.84
Kamper [50] HTN CsA Renal Tr Minority M median age 47, W median age 47 N/A 10:16 N/A 7.90 (median), 4.87-11.60 (range) N/A
Schmidt [53] HTN CsA Renal Tr Not reported 58 ± 12 N/A 1:12 N/A 7.8 ± 2.2 7.8 ± 1.8
Doehner [35] LV dysfxn (EF < 40%), hyperUA >400 umol/L Not reported 68 ± 2 69 ± 3 100% male 100% male 8.99 ± 0.37 9.88 ± 0.62
Chanard [54] HTN CsA Renal Tr Not reported 45.2 ± 9.9 48.2 ± 11.5 7:17 8:16 8.11 ± 1.66 7.56 ± 1.65
Siu [48] sCr 120-400 umol/L Majority 47.7 ± 12.9 48.8 ± 16.8 9:4 13:15 9.75 ± 1.18 9.92 ± 1.68
Liu [36] CKD (120-400 umol/L) and hyperUA Not reported 45.6 ± 12.5 46.5 ± 13. 8 8:16 10:13 9.73 ± 0.20 9.92 ± 0.26
Sarris [34] hyperUA > 7 mg/dL, mild-mod CKD, sCr >1.5, <3.0 mg/dL Not reported 49.2 ± 17.3 50.4 ± 15.8 8:10 11:7 8.88 ± 1.26 9.16 ± 1.46
Lei [40] CKD with hyperUA Not reported 48.6 ± 10.2 49.5 ± 9.8 9:20 9:19 8.84 ± 1.45 8.70 ± 1.41
Malaguarnera [55] hyperUA, 65-85 yrs, sCr 2.5 mg/dl Approximately half 75.6 ± 8.4 76.4 ± 8.1 15:5 12:6 10.9 ± 2.9 10.3 ± 3.1
Nouri-Majalan [52] Pts undergoing CABG and eGFR < 60 Not reported 65 ± 9.5 61 ± 7.90 13:17 16:14 Not reported Not reported
Deng [37] CKD Not reported 60.0 ± 11.1 58.8 ± 9.4 15:14 14:18 8.59 ± 1.01 8.93 ± 0.96
Goicoechea [44] CKD Stage 3-5 Majority 72.1 ± 7.9 71.4 ± 9.5 Not reported Not reported 7.8 ± 2.1 7.3 ± 1.6
Momeni [46] T2DM Nephropathy Majority 56.3 ± 10.6 59.1 ± 10.6 11:9 11:9 5.96 ± 1.21 6.5 ± 2.2
Shen [38] CKD with hyperUA Not reported 47.1 ± 11.8 47.6 ± 12.4 8:18 9:17 9.01 ± 1.38 8.89 ± 1.50
Kao [45] LVH and CKD Stage 3 Majority 70.6 ± 6.9 73.7 ± 5.3 59% male 46% male 7.39 ± 1.5 7.06 ± 1.3
Tan [39] T2DM nephropathy eGFR, 30-60 ml/min/1.73 m2 Majority 59.3 ± 9.2 58.6 ± 8.3 35:37 33:35 8.93 ± 0.96 8.60 ± 1.01
Shi [47] IgA nephropathy and hyperUA Excluded 39.7 ± 10.0 40.1 ± 10.8 8:13 10:9 7.9 ± 1.1 7.8 ± 1.1